In Patients with Metastatic Pancreas Cancers, Evaluation of the Relationship Between Neutrophil Lymphocide Ratio, Trombocyte Index, Systemic Immune-inflamation Index and Clinical, Pathologic and Prognostic Factors

Abstract

Objectives: In this study, we aimed to determine whether integrated markers that better reflect local immune re- sponse and systemic inflammation and based on clinically available peripheral neutrophil, lymphocyte and platelet counts are associated with treatment response and survival in pancreatic cancers. Methods: We retrospectively evaluated the clinical, pathological and prognostic features of 75 patients who were diag- nosed with metastatic pancreatic adenocarcinoma and who treated between January 1, 2012 and September 1, 2019 at Trakya University Medical Faculty, Medical Oncology Department. Since systemic inflammation markers did not have agreed threshold values in the literature, we determined the median values to be used as threshold values in our study. Results: In our study; We found that the overall survival was longer in patients with lower than NLR median value (<3) (p=0.001). We determined that the high platelet count (?235.10³) was related to longer progression-free sur - vival (p=0.02) and similarly, higher PCT (?0.22) was related to longer progression-free survival (p=0.01). We found that the overall survival of patients with an ECOG score of 0-1 was longer than that of patients with an ECOG score of 2 (p=0.003). We determined that the overall survival in patients with the first series of disease control was longer than those without disease control (p=0.002). Conclusion: Our study showed that NLR may be an independent marker predicting overall survival in patients with metastatic pancreatic cancer, and progression-free survival is associated with platelet count and PCT.